-
(
PrasadV
MailankodyS.
The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc
2016; 91: 707–712.27261866)
PrasadV
MailankodyS.
The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc
2016; 91: 707–712.27261866
PrasadV
MailankodyS.
The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc
2016; 91: 707–712.27261866,
PrasadV
MailankodyS.
The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc
2016; 91: 707–712.27261866
-
(
HurwitzH
FehrenbacherL
NovotnyW
, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med
2004; 350: 2335–2342.15175435)
HurwitzH
FehrenbacherL
NovotnyW
, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med
2004; 350: 2335–2342.15175435
HurwitzH
FehrenbacherL
NovotnyW
, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med
2004; 350: 2335–2342.15175435,
HurwitzH
FehrenbacherL
NovotnyW
, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med
2004; 350: 2335–2342.15175435
-
(
PorschenR
ArkenauHT
KubickaS
, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol
2007; 25: 4217–4223.17548840)
PorschenR
ArkenauHT
KubickaS
, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol
2007; 25: 4217–4223.17548840
PorschenR
ArkenauHT
KubickaS
, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol
2007; 25: 4217–4223.17548840,
PorschenR
ArkenauHT
KubickaS
, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol
2007; 25: 4217–4223.17548840
-
B.
Holleczek,
S.
Rossi,
Agius
Domenic,
K.
Innos,
P.
Minicozzi,
S.
Francisci,
M.
Hackl,
N.
Eisemann,
H.
Brenner
(2015)
On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study.
European journal of cancer, 51 15
-
N.
Tebbutt,
K.
Wilson,
V.
Gebski,
M.
Cummins,
D.
Zannino,
G.
Hazel,
B.
Robinson,
A.
Broad,
V.
Ganju,
S.
Ackland,
G.
Forgeson,
D.
Cunningham,
Mark
Saunders,
Martin
Stockler,
Y.
Chua,
J.
Zalcberg,
R.
Simes,
Timothy
Price
(2010)
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 19
-
J.
Tol,
M.
Koopman,
C.
Rodenburg,
A.
Cats,
G.
Creemers,
J.
Schrama,
F.
Erdkamp,
A.
Vos,
L.
Mol,
N.
Antonini,
C.
Punt
(2007)
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 4
-
C.
Fuchs,
J.
Marshall,
E.
Mitchell,
R.
Wierzbicki,
V.
Ganju,
M.
Jeffery,
J.
Schulz,
D.
Richards,
Raoudha
Soufi-Mahjoubi,
Benjamin
Wang,
J.
Barrueco
(2007)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 30
-
M.
Koopman,
N.
Antonini,
J.
Douma,
J.
Wals,
A.
Honkoop,
F.
Erdkamp,
R.
Jong,
C.
Rodenburg,
G.
Vreugdenhil,
O.
Loosveld,
A.
Bochove,
Harm
Sinnige,
G.
Creemers,
M.
Tesselaar,
P.
Slee,
M.
Werter,
L.
Mol,
O.
Dalesio,
C.
Punt
(2007)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
The Lancet, 370
-
F.
Loupakis,
C.
Cremolini,
G.
Masi,
S.
Lonardi,
V.
Zagonel,
L.
Salvatore,
E.
Cortesi,
G.
Tomasello,
M.
Ronzoni,
R.
Spadi,
A.
Zaniboni,
G.
Tonini,
A.
Buonadonna,
D.
Amoroso,
S.
Chiara,
C.
Carlomagno,
C.
Boni,
G.
Allegrini,
L.
Boni,
A.
Falcone
(2014)
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
The New England journal of medicine, 371 17
-
E.
Cutsem,
C.
Köhne,
E.
Hitre,
J.
Zaluski,
Chung-Rong
Chien,
A.
Makhson,
G.
D'Haens,
T.
Pintér,
R.
Lim,
G.
Bodoky,
J.
Roh,
G.
Folprecht,
P.
Ruff,
C.
Stroh,
S.
Tejpar,
M.
Schlichting,
J.
Nippgen,
P.
Rougier
(2009)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
The New England journal of medicine, 360 14
-
G.
Gatta,
G.
Zigon,
T.
Aareleid,
E.
Ardanaz,
M.
Bielska-Lasota,
J.
Galceran,
S.
Góźdź,
T.
Hakulinen,
C.
Martínez-García,
I.
Pleško,
M.
Žakelj,
J.
Rachtan,
G.
Tagliabue,
M.
Vercelli,
J.
Faivre
(2010)
Patterns of care for European colorectal cancer patients diagnosed 1996–1998: A EUROCARE High Resolution Study
Acta Oncologica, 49
-
(
GattaG
ZigonG
AareleidT
, et al. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCARE high resolution study. Acta Oncol
2010; 49: 776–783.20429733)
GattaG
ZigonG
AareleidT
, et al. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCARE high resolution study. Acta Oncol
2010; 49: 776–783.20429733
GattaG
ZigonG
AareleidT
, et al. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCARE high resolution study. Acta Oncol
2010; 49: 776–783.20429733,
GattaG
ZigonG
AareleidT
, et al. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCARE high resolution study. Acta Oncol
2010; 49: 776–783.20429733
-
(
SeymourMT
ThompsonLC
WasanHS
, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet
2011; 377: 1749–1759.21570111)
SeymourMT
ThompsonLC
WasanHS
, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet
2011; 377: 1749–1759.21570111
SeymourMT
ThompsonLC
WasanHS
, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet
2011; 377: 1749–1759.21570111,
SeymourMT
ThompsonLC
WasanHS
, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet
2011; 377: 1749–1759.21570111
-
L.
Saltz,
S.
Clarke,
E.
Díaz-Rubio,
W.
Scheithauer,
A.
Figer,
R.
Wong,
S.
Koski,
M.
Lichinitser,
T.S.
Yang,
F.
Rivera,
F.
Couture,
F.
Sirzén,
J.
Cassidy
(2023)
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology, 41
-
(
SaltzLB
ClarkeS
Diaz-RubioE
, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol
2008; 26: 2013–2019.18421054)
SaltzLB
ClarkeS
Diaz-RubioE
, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol
2008; 26: 2013–2019.18421054
SaltzLB
ClarkeS
Diaz-RubioE
, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol
2008; 26: 2013–2019.18421054,
SaltzLB
ClarkeS
Diaz-RubioE
, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol
2008; 26: 2013–2019.18421054
-
(
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593)
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593,
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
-
R.
Goldberg,
D.
Sargent,
R.
Morton,
C.
Fuchs,
R.
Ramanathan,
S.
Williamson,
B.
Findlay,
H.
Pitot,
S.
Alberts
(2004)
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 1
-
(
ChibaudelB
Maindrault-GoebelF
LledoG
, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol
2009; 27: 5727–5733.19786657)
ChibaudelB
Maindrault-GoebelF
LledoG
, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol
2009; 27: 5727–5733.19786657
ChibaudelB
Maindrault-GoebelF
LledoG
, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol
2009; 27: 5727–5733.19786657,
ChibaudelB
Maindrault-GoebelF
LledoG
, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol
2009; 27: 5727–5733.19786657
-
M.
Abdel-Rahman,
D.
Stockton,
B.
Rachet,
T.
Hakulinen,
M.
Coleman
(2009)
What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
British Journal of Cancer, 101
-
M.
Seymour,
T.
Maughan,
J.
Ledermann,
C.
Topham,
R.
James,
S.
Gwyther,
David
Smith,
S.
Shepherd,
A.
Maraveyas,
D.
Ferry,
A.
Meade,
L.
Thompson,
G.
Griffiths,
M.
Parmar,
R.
Stephens
(2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
The Lancet, 370
-
A.
Venook,
D.
Niedzwiecki,
H.
Lenz,
F.
Innocenti,
B.
Fruth,
J.
Meyerhardt,
D.
Schrag,
C.
Greene,
B.
O'Neil,
J.
Atkins,
S.
Berry,
B.
Polite,
E.
O’Reilly,
R.
Goldberg,
H.
Hochster,
R.
Schilsky,
M.
Bertagnolli,
A.
El-Khoueiry,
P.
Watson,
A.
Benson,
D.
Mulkerin,
R.
Mayer,
C.
Blanke
(2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
JAMA, 317
-
Li
Ying
(2009)
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
(
KoopmanM
AntoniniNF
DoumaJ
, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet
2007; 370: 135–142.17630036)
KoopmanM
AntoniniNF
DoumaJ
, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet
2007; 370: 135–142.17630036
KoopmanM
AntoniniNF
DoumaJ
, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet
2007; 370: 135–142.17630036,
KoopmanM
AntoniniNF
DoumaJ
, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet
2007; 370: 135–142.17630036
-
(
BerkeyCS
HoaglinDC
MostellerF
, et al. A random-effects regression model for meta-analysis. Stat Med
1995; 14: 395–411.7746979)
BerkeyCS
HoaglinDC
MostellerF
, et al. A random-effects regression model for meta-analysis. Stat Med
1995; 14: 395–411.7746979
BerkeyCS
HoaglinDC
MostellerF
, et al. A random-effects regression model for meta-analysis. Stat Med
1995; 14: 395–411.7746979,
BerkeyCS
HoaglinDC
MostellerF
, et al. A random-effects regression model for meta-analysis. Stat Med
1995; 14: 395–411.7746979
-
(
ExarchakouA
RachetB
BelotA
, et al. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996–2013: population based study. BMJ
2018; 360: k764.)
ExarchakouA
RachetB
BelotA
, et al. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996–2013: population based study. BMJ
2018; 360: k764.
ExarchakouA
RachetB
BelotA
, et al. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996–2013: population based study. BMJ
2018; 360: k764.,
ExarchakouA
RachetB
BelotA
, et al. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996–2013: population based study. BMJ
2018; 360: k764.
-
A.
Bacon,
Kwok-on.
Wong,
M.
Fernando,
B.
Rous,
R.
Hill,
S.
Collins,
John
BroggioJ,
S.
Strauss
(2022)
Incidence and survival of soft tissue sarcoma in England between 2013 and 2017, an analysis from the National Cancer Registration and Analysis Service
International Journal of Cancer, 152
-
(
Abdel-RahmanM
StocktonD
RachetB
, et al. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
Br J Cancer
2009; 101(Suppl. 2): S115–S124.)
Abdel-RahmanM
StocktonD
RachetB
, et al. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
Br J Cancer
2009; 101(Suppl. 2): S115–S124.
Abdel-RahmanM
StocktonD
RachetB
, et al. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
Br J Cancer
2009; 101(Suppl. 2): S115–S124.,
Abdel-RahmanM
StocktonD
RachetB
, et al. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?
Br J Cancer
2009; 101(Suppl. 2): S115–S124.
-
(
GoldbergRM
SargentDJ
MortonRF
, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol
2004; 22: 23–30.14665611)
GoldbergRM
SargentDJ
MortonRF
, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol
2004; 22: 23–30.14665611
GoldbergRM
SargentDJ
MortonRF
, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol
2004; 22: 23–30.14665611,
GoldbergRM
SargentDJ
MortonRF
, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol
2004; 22: 23–30.14665611
-
A.
Jemal,
R.
Siegel,
Jiemin
Ma,
F.
Islami,
C.
DeSantis,
Ann
Sauer,
Edgar
Simard,
E.
Ward
(2015)
Inequalities in premature death from colorectal cancer by state.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 8
-
(
MaughanTS
MeadeAM
AdamsRA
, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
Br J Cancer
2014; 110: 2178–2186.24743706)
MaughanTS
MeadeAM
AdamsRA
, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
Br J Cancer
2014; 110: 2178–2186.24743706
MaughanTS
MeadeAM
AdamsRA
, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
Br J Cancer
2014; 110: 2178–2186.24743706,
MaughanTS
MeadeAM
AdamsRA
, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
Br J Cancer
2014; 110: 2178–2186.24743706
-
(
DonnellyC
HartN
McCrorieAD
, et al. Predictors of an early death in patients diagnosed with colon cancer: a retrospective case-control study in the UK. BMJ Open
2019; 9: e026057.)
DonnellyC
HartN
McCrorieAD
, et al. Predictors of an early death in patients diagnosed with colon cancer: a retrospective case-control study in the UK. BMJ Open
2019; 9: e026057.
DonnellyC
HartN
McCrorieAD
, et al. Predictors of an early death in patients diagnosed with colon cancer: a retrospective case-control study in the UK. BMJ Open
2019; 9: e026057.,
DonnellyC
HartN
McCrorieAD
, et al. Predictors of an early death in patients diagnosed with colon cancer: a retrospective case-control study in the UK. BMJ Open
2019; 9: e026057.
-
A.
Falcone,
S.
Ricci,
I.
Brunetti,
E.
Pfanner,
G.
Allegrini,
C.
Barbara,
L.
Crinò,
G.
Benedetti,
W.
Evangelista,
L.
Fanchini,
E.
Cortesi,
V.
Picone,
S.
Vitello,
S.
Chiara,
C.
Granetto,
G.
Porcile,
L.
Fioretto,
C.
Orlandini,
M.
Andreuccetti,
G.
Masi
(2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
-
(
JemalA
SiegelRL
MaJ
, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol
2015; 33: 829–835.25385725)
JemalA
SiegelRL
MaJ
, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol
2015; 33: 829–835.25385725
JemalA
SiegelRL
MaJ
, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol
2015; 33: 829–835.25385725,
JemalA
SiegelRL
MaJ
, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol
2015; 33: 829–835.25385725
-
(
StintzingS
HeinemannV.
A still missing piece of the FIRE-3 puzzle – authors’ reply. Lancet Oncol
2016; 17: e516.)
StintzingS
HeinemannV.
A still missing piece of the FIRE-3 puzzle – authors’ reply. Lancet Oncol
2016; 17: e516.
StintzingS
HeinemannV.
A still missing piece of the FIRE-3 puzzle – authors’ reply. Lancet Oncol
2016; 17: e516.,
StintzingS
HeinemannV.
A still missing piece of the FIRE-3 puzzle – authors’ reply. Lancet Oncol
2016; 17: e516.
-
C.
Tournigand,
T.
André,
E.
Achille,
G.
Lledo,
M.
Flesh,
D.
Mery-mignard,
E.
Quinaux,
C.
Couteau,
M.
Buyse,
G.
Ganem,
B.
Landi,
P.
Colin,
C.
Louvet,
A.
Gramont
(2023)
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Journal of Clinical Oncology, 41
-
J.
Douillard,
K.
Oliner,
S.
Siena,
J.
Tabernero,
R.
Burkes,
M.
Barugel,
Y.
Humblet,
G.
Bodoky,
D.
Cunningham,
J.
Jassem,
F.
Rivera,
I.
Kocáková,
P.
Ruff,
M.
Błasińska-Morawiec,
M.
Šmakal,
J.
Canon,
M.
Rother,
R.
Williams,
A.
Rong,
J.
Wiezorek,
R.
Sidhu,
S.
Patterson
(2013)
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
The New England journal of medicine, 369 11
-
C.
Tournigand,
A.
Cervantes,
A.
Figer,
G.
Lledo,
M.
Flesch,
M.
Buyse,
L.
Mineur,
E.
Carola,
P.
Etienne,
F.
Rivera,
I.
Chirivella,
N.
Perez-staub,
C.
Louvet,
T.
André,
I.
Tabah-Fisch,
A.
Gramont
(2006)
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
-
C.
Berkey,
D.
Hoaglin,
F.
Mosteller,
G.
Colditz
(1995)
A random-effects regression model for meta-analysis.
Statistics in medicine, 14 4
-
(
BrownS
CastelliM
HunterDJ
, et al. How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med
2014; 116: 56–63.24980792)
BrownS
CastelliM
HunterDJ
, et al. How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med
2014; 116: 56–63.24980792
BrownS
CastelliM
HunterDJ
, et al. How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med
2014; 116: 56–63.24980792,
BrownS
CastelliM
HunterDJ
, et al. How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med
2014; 116: 56–63.24980792
-
M.
Seymour,
Lindsay
Thompson,
Harpreet
Wasan,
G.
Middleton,
Alison
Brewster,
Stephen
Shepherd,
M
O'Mahony,
T.
Maughan,
M.
Parmar,
Ruth
Langley
(2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Lancet, 377
-
(
FuchsCS
MarshallJ
MitchellE
, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol
2007; 25: 4779–4786.17947725)
FuchsCS
MarshallJ
MitchellE
, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol
2007; 25: 4779–4786.17947725
FuchsCS
MarshallJ
MitchellE
, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol
2007; 25: 4779–4786.17947725,
FuchsCS
MarshallJ
MitchellE
, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol
2007; 25: 4779–4786.17947725
-
S.
Walters,
S.
Benitez-Majano,
P.
Muller,
M.
Coleman,
C.
Allemani,
J.
Butler,
M.
Peake,
M.
Guren,
B.
Glimelius,
S.
Bergström,
L.
Påhlman,
B.
Rachet
(2015)
Is England closing the international gap in cancer survival?
British Journal of Cancer, 113
-
(
SouglakosJ
AndroulakisN
SyrigosK
, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer
2006; 94: 798–805.16508637)
SouglakosJ
AndroulakisN
SyrigosK
, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer
2006; 94: 798–805.16508637
SouglakosJ
AndroulakisN
SyrigosK
, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer
2006; 94: 798–805.16508637,
SouglakosJ
AndroulakisN
SyrigosK
, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer
2006; 94: 798–805.16508637
-
A.
Exarchakou,
B.
Rachet,
A.
Belot,
C.
Maringe,
M.
Coleman
(2018)
Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based study
The BMJ, 360
-
B.
Chibaudel,
F.
Maindrault-Goebel,
G.
Lledo,
L.
Mineur,
T.
André,
M.
Bennamoun,
M.
Mabro,
P.
Artru,
E.
Carola,
M.
Flesch,
O.
Dupuis,
P.
Colin,
A.
Larsen,
P.
Afchain,
C.
Tournigand,
C.
Louvet,
A.
Gramont
(2009)
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 34
-
M.
Sant,
R.
Capocaccia,
A.
Verdecchia,
G.
Gatta,
A.
Micheli,
A.
Mariotto,
T.
Hakulinen,
F.
Berrino
(1995)
Comparisons of colon–cancer survival among european countries: The eurocare study
International Journal of Cancer, 63
-
Routes to diagnosis
-
E.
Díaz-Rubio,
A.
Gómez-España,
B.
Massutí,
J.
Sastre,
A.
Abad,
M.
Valladares,
F.
Rivera,
M.
Safont,
P.
Prado,
M.
Gallén,
E.
González,
E.
Marcuello,
M.
Benavides,
C.
Fernández‐Martos,
F.
Losa,
P.
Escudero,
A.
Arriví,
A.
Cervantes,
R.
Dueñas,
A.
López-Ladrón,
A.
Lacasta,
M.
Llanos,
J.
Tabernero,
A.
Antón,
E.
Aranda
(2012)
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
The oncologist, 17 1
-
(
MoosmannN
Von WeikersthalLF
Vehling-KaiserU
, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol
2011; 29: 1050–1058.21300933)
MoosmannN
Von WeikersthalLF
Vehling-KaiserU
, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol
2011; 29: 1050–1058.21300933
MoosmannN
Von WeikersthalLF
Vehling-KaiserU
, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol
2011; 29: 1050–1058.21300933,
MoosmannN
Von WeikersthalLF
Vehling-KaiserU
, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol
2011; 29: 1050–1058.21300933
-
(
National Cancer Registration and Analysis Service. Routes to diagnosis, http://www.ncin.org.uk/publications/routes_to_diagnosis (2020, accessed 1 August 2020).)
National Cancer Registration and Analysis Service. Routes to diagnosis, http://www.ncin.org.uk/publications/routes_to_diagnosis (2020, accessed 1 August 2020).
National Cancer Registration and Analysis Service. Routes to diagnosis, http://www.ncin.org.uk/publications/routes_to_diagnosis (2020, accessed 1 August 2020).,
National Cancer Registration and Analysis Service. Routes to diagnosis, http://www.ncin.org.uk/publications/routes_to_diagnosis (2020, accessed 1 August 2020).
-
N.
Moosmann,
L.
Weikersthal,
U.
Vehling‐Kaiser,
M.
Stauch,
H.
Hass,
H.
Dietzfelbinger,
D.
Oruzio,
S.
Klein,
K.
Zellmann,
T.
Decker,
M.
Schulze,
W.
Abenhardt,
G.
Puchtler,
H.
Kappauf,
J.
Mittermüller,
C.
Haberl,
A.
Schalhorn,
A.
Jung,
S.
Stintzing,
V.
Heinemann
(2011)
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
O.
Dejardin,
B.
Rachet,
Eva
Morris,
Bouvier,
Jooste,
Robin
Haynes,
E.
Coombes,
David
Forman,
David
Forman,
Andrew
Jones,
Anne
Bouvier,
Guy
Launoy
(2013)
Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997–2004
British Journal of Cancer, 108
-
(
DejardinO
RachetB
MorrisE
, et al. Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997–2004. Br J Cancer
2013; 108: 775–783.23392081)
DejardinO
RachetB
MorrisE
, et al. Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997–2004. Br J Cancer
2013; 108: 775–783.23392081
DejardinO
RachetB
MorrisE
, et al. Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997–2004. Br J Cancer
2013; 108: 775–783.23392081,
DejardinO
RachetB
MorrisE
, et al. Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997–2004. Br J Cancer
2013; 108: 775–783.23392081
-
(
Van CutsemE
KohneCH
HitreE
, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med
2009; 360: 1408–1417.19339720)
Van CutsemE
KohneCH
HitreE
, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med
2009; 360: 1408–1417.19339720
Van CutsemE
KohneCH
HitreE
, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med
2009; 360: 1408–1417.19339720,
Van CutsemE
KohneCH
HitreE
, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med
2009; 360: 1408–1417.19339720
-
(
Diaz-RubioE
Gomez-EspanaA
MassutiB
, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist
2012; 17: 15–25.22234633)
Diaz-RubioE
Gomez-EspanaA
MassutiB
, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist
2012; 17: 15–25.22234633
Diaz-RubioE
Gomez-EspanaA
MassutiB
, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist
2012; 17: 15–25.22234633,
Diaz-RubioE
Gomez-EspanaA
MassutiB
, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist
2012; 17: 15–25.22234633
-
(
HolleczekB
RossiS
DomenicA
, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer
2015; 51: 2158–2168.26421819)
HolleczekB
RossiS
DomenicA
, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer
2015; 51: 2158–2168.26421819
HolleczekB
RossiS
DomenicA
, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer
2015; 51: 2158–2168.26421819,
HolleczekB
RossiS
DomenicA
, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer
2015; 51: 2158–2168.26421819
-
(
VenookAP
NiedzwieckiD
LenzHJ
, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA
2017; 317: 2392–2401.28632865)
VenookAP
NiedzwieckiD
LenzHJ
, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA
2017; 317: 2392–2401.28632865
VenookAP
NiedzwieckiD
LenzHJ
, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA
2017; 317: 2392–2401.28632865,
VenookAP
NiedzwieckiD
LenzHJ
, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA
2017; 317: 2392–2401.28632865
-
C.
Donnelly,
N.
Hart,
A.
McCrorie,
M.
Donnelly,
L.
Anderson,
L.
Ranaghan,
A.
Gavin
(2019)
Predictors of an early death in patients diagnosed with colon cancer: a retrospective case–control study in the UK
BMJ Open, 9
-
J.
Souglakos,
N.
Androulakis,
K.
Syrigos,
A.
Polyzos,
N.
Ziras,
A.
Athanasiadis,
S.
Kakolyris,
S.
Tsousis,
C.
Kouroussis,
L.
Vamvakas,
A.
Kalykaki,
G.
Samonis,
D.
Mavroudis,
V.
Georgoulias
(2006)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
British Journal of Cancer, 94
-
R.
Porschen,
H.
Arkenau,
S.
Kubicka,
R.
Greil,
T.
Seufferlein,
W.
Freier,
A.
Kretzschmar,
U.
Graeven,
A.
Grothey,
A.
Hinke,
W.
Schmiegel,
H.
Schmoll
(2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 27
-
M.
Dong
(2006)
OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study
Journal of Evidence-based Medicine
-
I.
Soerjomataram,
J.
Lortet-Tieulent,
D.
Parkin,
J.
Ferlay,
C.
Mathers,
D.
Forman,
F.
Bray
(2012)
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions
The Lancet, 380
-
(
KabbinavarFF
SchulzJ
McCleodM
, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol
2005; 23: 3697–3705.15738537)
KabbinavarFF
SchulzJ
McCleodM
, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol
2005; 23: 3697–3705.15738537
KabbinavarFF
SchulzJ
McCleodM
, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol
2005; 23: 3697–3705.15738537,
KabbinavarFF
SchulzJ
McCleodM
, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol
2005; 23: 3697–3705.15738537
-
S.
Majano,
C.
Girolamo,
B.
Rachet,
C.
Maringe,
M.
Guren,
B.
Glimelius,
L.
Iversen,
E.
Schnell,
K.
Lundqvist,
J.
Christensen,
M.
Morris,
M.
Coleman,
S.
Walters
(2019)
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
The Lancet. Oncology, 20
-
F.
Kabbinavar,
J.
Schulz,
M.
Mccleod,
T.
Patel,
J.
Hamm,
J.
Hecht,
R.
Mass,
B.
Perrou,
B.
Nelson,
W.
Novotny
(2005)
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
-
(
FalconeA
RicciS
BrunettiI
, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol
2007; 25: 1670–1676.17470860)
FalconeA
RicciS
BrunettiI
, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol
2007; 25: 1670–1676.17470860
FalconeA
RicciS
BrunettiI
, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol
2007; 25: 1670–1676.17470860,
FalconeA
RicciS
BrunettiI
, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol
2007; 25: 1670–1676.17470860
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
(
HechtJR
MitchellE
ChidiacT
, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol
2009; 27: 672–680.19114685)
HechtJR
MitchellE
ChidiacT
, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol
2009; 27: 672–680.19114685
HechtJR
MitchellE
ChidiacT
, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol
2009; 27: 672–680.19114685,
HechtJR
MitchellE
ChidiacT
, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol
2009; 27: 672–680.19114685
-
(
BokemeyerC
BondarenkoI
MakhsonA
, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol
2009; 27: 663–671.19114683)
BokemeyerC
BondarenkoI
MakhsonA
, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol
2009; 27: 663–671.19114683
BokemeyerC
BondarenkoI
MakhsonA
, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol
2009; 27: 663–671.19114683,
BokemeyerC
BondarenkoI
MakhsonA
, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol
2009; 27: 663–671.19114683
-
Richard
Adams,
A.
Meade,
M.
Seymour,
Richard
Wilson,
A.
Madi,
D.
Fisher,
S.
Kenny,
E.
Kay,
E.
Hodgkinson,
M.
Pope,
P.
Rogers,
H.
Wasan,
S.
Falk,
S.
Gollins,
T.
Hickish,
Eric
Bessell,
D.
Propper,
M.
Kennedy,
R.
Kaplan,
T.
Maughan
(2011)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
The Lancet. Oncology, 12
-
V.
Prasad,
S.
Mailankody
(2016)
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Mayo Clinic proceedings, 91 6
-
(
WaltersS
Benitez-MajanoS
MullerP
, et al. Is England closing the international gap in cancer survival?
Br J Cancer
2015; 113: 848–860.26241817)
WaltersS
Benitez-MajanoS
MullerP
, et al. Is England closing the international gap in cancer survival?
Br J Cancer
2015; 113: 848–860.26241817
WaltersS
Benitez-MajanoS
MullerP
, et al. Is England closing the international gap in cancer survival?
Br J Cancer
2015; 113: 848–860.26241817,
WaltersS
Benitez-MajanoS
MullerP
, et al. Is England closing the international gap in cancer survival?
Br J Cancer
2015; 113: 848–860.26241817
-
S.
Stintzing,
V.
Heinemann
(2016)
A still missing piece of the FIRE-3 puzzle - Authors' reply.
The Lancet. Oncology, 17 12
-
E.
Díaz-Rubio,
J.
Tabernero,
A.
Gómez-España,
B.
Massutí,
J.
Sastre,
M.
Chaves,
A.
Abad,
A.
Carrato,
B.
Queralt,
J.
Reina,
J.
Maurel,
E.
González-Flores,
J.
Aparicio,
F.
Rivera,
F.
Losa,
E.
Aranda
(2007)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 27
-
(
SantM
CapocacciaR
VerdecchiaA
, et al. Comparisons of colon-cancer survival among European countries: the Eurocare study. Int J Cancer
1995; 63: 43–48.7558450)
SantM
CapocacciaR
VerdecchiaA
, et al. Comparisons of colon-cancer survival among European countries: the Eurocare study. Int J Cancer
1995; 63: 43–48.7558450
SantM
CapocacciaR
VerdecchiaA
, et al. Comparisons of colon-cancer survival among European countries: the Eurocare study. Int J Cancer
1995; 63: 43–48.7558450,
SantM
CapocacciaR
VerdecchiaA
, et al. Comparisons of colon-cancer survival among European countries: the Eurocare study. Int J Cancer
1995; 63: 43–48.7558450
-
C.
Bokemeyer,
I.
Bondarenko,
A.
Makhson,
J.
Hartmann,
J.
Aparicio,
F.
Braud,
S.
Donea,
H.
Ludwig,
G.
Schuch,
C.
Stroh,
A.
Loos,
A.
Zubel,
P.
Koralewski
(2009)
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
A.
Downing,
E.
Morris,
N.
Corrigan,
D.
Sebag‐Montefiore,
P.
Finan,
James
Thomas,
M.
Chapman,
R.
Hamilton,
H.
Campbell,
D.
Cameron,
R.
Kaplan,
M.
Parmar,
R.
Stephens,
M.
Seymour,
W.
Gregory,
P.
Selby
(2016)
High hospital research participation and improved colorectal cancer survival outcomes: a population-based study
Gut, 66
-
R.
Angelis,
M.
Sant,
M.
Coleman,
S.
Francisci,
P.
Baili,
D.
Pierannunzio,
A.
Trama,
O.
Visser,
H.
Brenner,
E.
Ardanaz,
M.
Bielska-Lasota,
G.
Engholm,
A.
Nennecke,
S.
Siesling,
F.
Berrino,
R.
Capocaccia
(2014)
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.
The Lancet. Oncology, 15 1
-
(
MajanoSB
Di GirolamoC
RachetB
, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol
2019; 20: 74–87.30545752)
MajanoSB
Di GirolamoC
RachetB
, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol
2019; 20: 74–87.30545752
MajanoSB
Di GirolamoC
RachetB
, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol
2019; 20: 74–87.30545752,
MajanoSB
Di GirolamoC
RachetB
, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol
2019; 20: 74–87.30545752
-
(
TournigandC
AndreT
AchilleE
, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
2004; 22: 229–237.14657227)
TournigandC
AndreT
AchilleE
, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
2004; 22: 229–237.14657227
TournigandC
AndreT
AchilleE
, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
2004; 22: 229–237.14657227,
TournigandC
AndreT
AchilleE
, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
2004; 22: 229–237.14657227
-
F.
Bray,
J.
Ferlay,
I.
Soerjomataram,
R.
Siegel,
Lindsey
Torre,
A.
Jemal
(2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA: A Cancer Journal for Clinicians, 68
-
(
De AngelisR
SantM
ColemanMP
, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol
2014; 15: 23–34.24314615)
De AngelisR
SantM
ColemanMP
, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol
2014; 15: 23–34.24314615
De AngelisR
SantM
ColemanMP
, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol
2014; 15: 23–34.24314615,
De AngelisR
SantM
ColemanMP
, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol
2014; 15: 23–34.24314615
-
(
LoupakisF
CremoliniC
MasiG
, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med
2014; 371: 1609–1618.25337750)
LoupakisF
CremoliniC
MasiG
, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med
2014; 371: 1609–1618.25337750
LoupakisF
CremoliniC
MasiG
, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med
2014; 371: 1609–1618.25337750,
LoupakisF
CremoliniC
MasiG
, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med
2014; 371: 1609–1618.25337750
-
(
TolJ
KoopmanM
RodenburgCJ
, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol
2008; 19: 734–738.18272912)
TolJ
KoopmanM
RodenburgCJ
, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol
2008; 19: 734–738.18272912
TolJ
KoopmanM
RodenburgCJ
, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol
2008; 19: 734–738.18272912,
TolJ
KoopmanM
RodenburgCJ
, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol
2008; 19: 734–738.18272912
-
(
TebbuttNC
WilsonK
GebskiVJ
, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol
2010; 28: 3191–3198.20516443)
TebbuttNC
WilsonK
GebskiVJ
, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol
2010; 28: 3191–3198.20516443
TebbuttNC
WilsonK
GebskiVJ
, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol
2010; 28: 3191–3198.20516443,
TebbuttNC
WilsonK
GebskiVJ
, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol
2010; 28: 3191–3198.20516443
-
Tim
Maughan,
A.
Meade,
R.
Adams,
S.
Richman,
R.
Butler,
D.
Fisher,
R.
Wilson,
B.
Jasani,
G.
Taylor,
G.
Williams,
J.
Sampson,
M.
Seymour,
L.
Nichols,
S.
Kenny,
Annmarie
Nelson,
C.
Sampson,
E.
Hodgkinson,
J.
Bridgewater,
D.
Furniss,
R.
Roy,
M.
Pope,
J.
Pope,
M.
Parmar,
P.
Quirke,
R.
Kaplan
(2014)
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
British Journal of Cancer, 110
-
(
DowningA
MorrisEJ
CorriganN
, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut
2017; 66: 89–96.27797935)
DowningA
MorrisEJ
CorriganN
, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut
2017; 66: 89–96.27797935
DowningA
MorrisEJ
CorriganN
, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut
2017; 66: 89–96.27797935,
DowningA
MorrisEJ
CorriganN
, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut
2017; 66: 89–96.27797935
-
H.
Hurwitz,
L.
Fehrenbacher,
W.
Novotny,
T.
Cartwright,
J.
Hainsworth,
W.
Heim,
J.
Berlin,
A.
Baron,
S.
Griffing,
E.
Holmgren,
N.
Ferrara,
G.
Fyfe,
B.
Rogers,
R.
Ross,
F.
Kabbinavar
(2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine, 350 23
-
S.
Brown,
Michele
Castelli,
D.
Hunter,
J.
Erskine,
P.
Vedsted,
C.
Foot,
G.
Rubin
(2014)
How might healthcare systems influence speed of cancer diagnosis: A narrative review
Social Science & Medicine (1982), 116
-
(
SoerjomataramI
Lortet-TieulentJ
ParkinDM
, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet
2012; 380: 1840–1850.23079588)
SoerjomataramI
Lortet-TieulentJ
ParkinDM
, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet
2012; 380: 1840–1850.23079588
SoerjomataramI
Lortet-TieulentJ
ParkinDM
, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet
2012; 380: 1840–1850.23079588,
SoerjomataramI
Lortet-TieulentJ
ParkinDM
, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet
2012; 380: 1840–1850.23079588
-
(
AdamsRA
MeadeAM
SeymourMT
, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol
2011; 12: 642–653.21641867)
AdamsRA
MeadeAM
SeymourMT
, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol
2011; 12: 642–653.21641867
AdamsRA
MeadeAM
SeymourMT
, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol
2011; 12: 642–653.21641867,
AdamsRA
MeadeAM
SeymourMT
, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol
2011; 12: 642–653.21641867
-
(
DouillardJY
OlinerKS
SienaS
, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med
2013; 369: 1023–1034.24024839)
DouillardJY
OlinerKS
SienaS
, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med
2013; 369: 1023–1034.24024839
DouillardJY
OlinerKS
SienaS
, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med
2013; 369: 1023–1034.24024839,
DouillardJY
OlinerKS
SienaS
, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med
2013; 369: 1023–1034.24024839